ENHYPEN Sell Out All 3 Seoul Dates for BLOOD SAGA Before General Sale

ENHYPEN sold out all three Seoul dates for BLOOD SAGA before general sale even opened, turning the May 1 to May 3 run at KSPO Dome into one of the clearest early signals of the tour's demand curve. According to NOL ticket's official notice, the three-show kickoff is scheduled for May 1 at 7 PM KST, May 2 at 6 PM KST, and May 3 at 5 PM KST, with both in-person and online livestream plans attached to the Seoul stop. BELIFT LAB confirmed on April 9 that the fan club presale sold out, as reported by The Korea Herald, and the speed of that result immediately pushed the opening weekend into must-watch territory for the wider tour. That matters because BLOOD SAGA is not opening from a maybe. It is opening from scarcity.

For a group that has spent the past year moving like a top-tier touring act, this is the kind of sellout that sharpens the market conversation. The Seoul shows are not just hometown dates. They are the launch point for ENHYPEN's fourth world tour, and Chosun English reports the full run stretches across 21 cities with the group's first South American stops included in the routing. We have seen plenty of K-pop tours flex global ambition on paper. Selling out the first three nights before general sale is the stronger flex because it shows the fan base is still willing to move fast, pay premium, and fight the queue before the wider public even gets a shot. In a touring economy where demand signals can get inflated by hype alone, ENHYPEN just posted the real number that matters. Seats gone.

ENHYPEN's BLOOD SAGA Seoul dates sold out during fan club presale

BELIFT LAB said the Seoul concerts sold out through the exclusive fan offering, according to The Korea Herald, which frames the result as a complete presale wipeout before April 10's general sale window. The official NOL ticket notice backs up the event details and confirms the venue, showtimes, pricing tiers, and exclusive seller setup. That mix matters because presale sellouts can sometimes sound softer than they are. This one does not. NOL listed sound check seats at KRW 220,000, M&G seats at KRW 253,000, and general seats at KRW 165,000, so fans were not rushing low-cost inventory. They were buying into a premium stadium-scale weekend built around ENHYPEN's new era. If you wanted a clean proof point for how strong the group's domestic core still is, Seoul just delivered it in three straight nights.

The KSPO Dome kickoff sets the tone for ENHYPEN's fourth world tour

BLOOD SAGA is set to open at KSPO Dome on May 1, May 2, and May 3, 2026, and that Seoul run now looks less like a ceremonial launch and more like the pressure point that validates the entire routing. According to Chosun English, the tour covers 21 cities and includes ENHYPEN's first standalone stops in South America, followed by dates in the United States, Asia, and Europe. That bigger map turns the Seoul sellout into more than local fandom noise. It becomes the first live business case for the whole tour. We have been here before with K-pop acts that dominate streaming but still have to prove how far ticket demand can stretch across regions. ENHYPEN is entering this cycle from a stronger position than that. The Seoul result says the base is locked in before the tour even leaves Korea.

Why the presale result matters more than a standard sold-out headline

A general sold-out headline is nice. A presale sellout is more revealing because it isolates the most committed part of the fandom and shows how quickly that core can absorb premium inventory. In ENHYPEN's case, the domestic and global fan club presales were held on April 7 and April 8, and the tickets were already gone by the time BELIFT LAB spoke publicly on April 9, as reported across Korean and English-language coverage. That timeline tells you demand was immediate, not gradually built through later marketing pushes. It also gives the upcoming general sale a different kind of tension. Fans are no longer asking whether Seoul will move. They are asking whether anything meaningful is left to buy. Over on Reddit's ENHYPEN communities, the reaction has been exactly what you would expect: excitement, panic, queue strategy, and a lot of people already treating the kickoff as one of the hardest tickets in the run.

If you need extra context, this is also why ENHYPEN remains one of HYBE's strongest live properties even after the turbulence around the group's recent news cycle. The act's touring brand is still intact, and the fandom's buying behavior keeps proving it. For HITKULTR readers, the bigger takeaway is simple. ENHYPEN is walking into BLOOD SAGA with scarcity already baked into the narrative, and that tends to make every later stop feel hotter by association. It also gives HYBE and BELIFT LAB the exact opening-week headline they want: not just a new world tour, but a world tour that already looks difficult to get into. That is the kind of rollout fans read as momentum and the market reads as leverage.

For broader group context, revisit our earlier ENHYPEN coverage. Just do not confuse the narratives. That story was about lineup change. This one is about demand, and demand is clearly not the problem.